These indications prompted us to test the effect of the WNT5A agonist Foxy-5 on the invasion of both DU145 (with a low endogenous expression of WNT5A) and PC3 prostate cancer cells (with high endogenous level of WNT5A). This evidence concerns the gene WNT5A and prostate carcinoma.